Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous "Computational Biologist" agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. The platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. The full press release is available at https://ibn.fm/9sIIl.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The launch of ZetaOmics represents a significant step for Lantern in broadening the application of its AI capabilities. By automating complex bioinformatics analyses, the platform has the potential to accelerate research and improve reproducibility in cancer biology. The commercial availability of withZeta.ai as a subscription-based research platform creates a new revenue stream for the company, which operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. This move could position Lantern to compete more broadly in the computational biology market, extending its reach beyond its core focus on rare cancers.
